Interventions of Interest:

  • etranacogene dezaparvovec (Hemgenix, CSL Behring)
  • valoctocogene roxaparvovec (Roctavian ™; BioMarin)

ICER reviewed valoctocogene roxaparvovec for hemophilia A in 2020 (Valoctocogene Roxaparvovec and Emicizumab for Hemophilia A without Inhibitors: Effectiveness and Value). In this review, the two interventions will be considered separately as if we were performing two independent reviews in two different populations.

For questions or to request a Spanish translated Report-at-a-Glance for this assessment, please contact Liis Shea, Program Director, at lshea@icer.org.

View the Key Stakeholder List.